Citation, DOI, disclosures and article data
At the time the article was created Jay Dayalal Tank had no recorded disclosures.View Jay Dayalal Tank's current disclosures
Iodine-131 (131I or I-131) is a radioisotope of iodine, which is used in the diagnosis, treatment and theranostic approach (diagnostic scan and radionuclide therapy 3 ) of thyroid lesions. It is one of the oldest radiotracers used in nuclear medicine, in use for over 50 years. It is predominately used in thyroid ablation therapy, for patients post-thyroidectomy, and for metastatic thyroid cancer.
I-131 is selectively taken up by thyroid follicular cells with the help of sodium-iodine symporters and undergoes trapping and organification. Of note, sodium-iodine symporter cell surface expression is in turn stimulated by thyroid-stimulating hormone (TSH) 2.
beta emission (which damages the thyroid tissue)
gamma emission (with a 364 keV photopeak used in imaging)
half-life: approximately 8 days
The high energy gamma emission leads to poor-resolution images. However, the long half-life is beneficial for detecting occult metastatic disease because imaging can be done over a few days after oral administration of the radiopharmaceutical.
I-131 is predominately used in ablation therapy for patients post thyroidectomy for thyroid cancer. Generally, a surgeon performs a near-total thyroidectomy (in order to preserve parathyroid function and due to the inherent difficulty in locating thyroid tissue deep within the neck). Therefore, an I-131 scan is first performed after the patient has had surgery to look for and ablate functioning remnant thyroid tissue.
History and etymology
The use of radioiodine in clinical practice was introduced in the 1940s by Saul Hertz, MD and director of the thyroid unit of Massachusetts General Hospital 4.
- 1. Mettler FA, Guiberteau MJ. Essentials of Nuclear Medicine Imaging: Expert Consult - Online and Print, 6e. Saunders. ISBN:1455701041. Read it at Google Books - Find it at Amazon
- 2. Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I- symporter (NIS): mechanism and medical impact. (2014) Endocrine reviews. 35 (1): 106-49. doi:10.1210/er.2012-1036 - Pubmed
- 3. Choudhury P, Choudhury GM, Choudhury. Differentiated thyroid cancer theranostics: radioiodine and beyond. (2018) The British journal of radiology. doi:10.1259/bjr.20180136 - Pubmed
- 4. Hertz B. A tribute to Dr. Saul Hertz: The discovery of the medical uses of radioiodine. (2019) World journal of nuclear medicine. 18 (1): 8-12. doi:10.4103/wjnm.WJNM_107_18 - Pubmed